1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Microbix Biosystems Inc.

Microbix Biosystems Inc.

MBXBF
Microbix Biosystems Inc.US flagOther OTC
0.22
USD
+0.01
- -
30.54MMarket Cap
Microbix Biosystems Inc.
MBXBF
(Other OTC)

Recent

price

0.22

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.13
0.11
0.11
0.11
0.12
0.11
0.11
0.12
0.13
0.14
0.1
0.16
0.14
0.12
0.18
0.13
0.11
Revenue per Share
-0.05
-0.05
-0.04
- -
- -
0.01
0.01
-0.04
-0.09
- -
-0.06
0.03
0.01
- -
0.03
-0.02
-0.04
Basic EPS, GAAP
-0.04
-0.02
-0.03
- -
-0.07
-0.05
-0.01
- -
-0.02
- -
-0.01
0.01
0.01
-0.02
0.02
-0.01
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.11
0.08
0.08
0.08
0.13
0.16
0.18
0.18
0.11
0.11
0.06
0.15
0.18
0.18
0.21
0.2
0.18
Book Value per Share
0.03
0.01
0.02
0.03
0.08
0.1
0.11
0.1
0.06
0.06
0.04
0.13
0.17
0.15
0.18
0.17
0.15
Tangible Book Value per Share
49
55
62
67
69
81
85
85
96
97
105
115
135
138
138
139
138
Basic Weighted Avg Shares
6
6
7
8
8
9
10
10
13
13
11
19
19
17
25
19
15
Sales/Revenue/Turnover
-25.54
-24.82
-25.24
9.85
15.68
12.3
8.82
-5.64
0.87
8.27
-4.98
26.01
13.68
-16.57
15.35
-8.48
-27.77
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
2
2
2
Depreciation Expense
-3
-3
-2
- -
- -
1
1
-4
-9
- -
-6
3
2
- -
4
-2
-5
Net Income, GAAP
- -
- -
- -
99.18
64.47
- -
- -
- -
- -
26.93
- -
- -
4.14
- -
4.1
- -
- -
Effective Tax Rate (%)
-39.28
-41.2
-35.82
0.02
2.01
6.92
7.86
-37.11
-68.91
0.24
-59.17
17.39
9.38
-0.24
13.86
-12.08
-31.72
Profit Margin (%)
1
1
- -
1
2
2
- -
- -
2
2
2
14
20
18
21
21
18
Working Capital
6
6
5
5
5
6
5
5
5
4
5
5
6
6
6
7
6
LT Debt
6
5
5
6
10
14
15
15
10
11
7
19
25
25
28
28
24
Total Equity
- -
- -
- -
0.06
3.5
- -
- -
- -
- -
4.75
- -
24.75
8.77
- -
11.33
- -
- -
Return on Invested Capital (%)
- -
- -
- -
0.07
3.53
- -
- -
- -
- -
4.75
- -
24.75
9.05
- -
13.35
- -
- -
Return on Capital (%)
-42.1
-49.27
-47.72
0.03
2.17
5.22
5.17
-24.81
-67.55
0.31
-72.6
25.69
8.22
-0.16
13.3
-8.01
-18.24
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
- -
1
- -
LT Borrowings
5
5
5
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
139
138
137
Market Capitalization
33
33
40

Working Capital

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
23
22
21
Cash, Cash Equivalents & STI
9
8
7
Accounts Receivable, Net
4
3
3
Inventories
9
10
11
Total Current Liabilities
3
4
3
Payables & Accruals
2
2
2
ST Debt
- -
1
- -
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.05%
45.32%
-1.8%
Free Cash Flow
-44.61%
-143.81%
-135.95%
Net Income, GAAP
-2,964.48%
-1,895.66%
-163.8%
Sales/Revenue/Turnover
11.56%
18.56%
-26.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8
6
5
6
25
2025
6
5
3
4
19
2026
4
3
4
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.03
2025
0.01
- -
-0.01
- -
-0.02
2026
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Mycenax Biotech Inc. (4726.TWO)
Medigen Vaccine Biologics Corp. (6547.TWO)
Adynxx, Inc. (ADYX)
Titan Pharmaceuticals, Inc. (TTNP)
Open Orphan Plc (ORPH.IR)
Sona Nanotech Inc. (SONA.CN)
Business
Microbix Biosystems Inc. develops and commercializes proprietary biological and technological solutions for the global diagnostics industry, including infectious disease antigens as key ingredients for immunoassays; quality assessment products (QAPs™) such as REDx™FLOQ®, PROCEEDx®, and ONBOARDx™ for proficiency testing, assay validation, and workflow quality control covering respiratory viruses (SARS-CoV-2, RSV, Flu A/B, parainfluenza, adenovirus), high-risk HPV, STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium), genital ulcers (HSV 1/2, VZV, Treponema pallidum, Monkeypox), gastrointestinal pathogens (C. difficile, Campylobacter, Rotavirus), and vaginal infections; DxTM™ viral transport medium and control elution buffers for specimen collection and stabilization; vial filling services with capacities up to 60,000 vials per day; and Kinlytic® urokinase, a biologic thrombolytic for blood clot clearance. The company serves over 100 multinational diagnostics firms, clinical labs, and accreditation agencies across North America, Europe, Asia-Pacific, and internationally, with products registered with FDA, Health Canada, EU IVDR, UK MHRA, and Australian TGA. Founded in 1988 and headquartered in Mississauga, Ontario, Canada, Microbix operates from three adjacent facilities supporting antigen production, medical device manufacturing, and R&D. Recent developments include a November 2025 partnership with SEKISUI Diagnostics for QAPs supporting COVID/Flu point-of-care assays on the Metrix® platform; launch of QUANTDx™ characterized reference materials; supply agreement with Bulgaria’s NCIPD for pathogen seedstocks; collaborations with EMQN for genetic-test EQA programs on Clopidogrel metabolism and antibiotic-induced hearing loss; execution of Sequel Pharma agreements advancing Kinlytic® toward US re-approval with US$4.0 million in milestones received since May 2023; $2.4 million from warrant exercises; recombinant antigen production expansion; multiple grants including $3.6 million from FedDev Ontario (repayment from 2026) and Ontario Together Fund; Normal Course Issuer Bids repurchasing shares; and Q1 fiscal 2025 revenues of $6.0 million with 40% recurring growth and net earnings of $0.9 million.

Company News

Company News APIChatGPT